XML 21 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Components
6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Components
Balance Sheet Components

Cash Equivalents and Available-for-sale Securities

Cash equivalents and available-for-sale securities consisted of the following (in thousands):
 
June 30, 2017
 
Amortized
Cost
 
Gross Unrealized
 
 
 
Gains
 
Losses
 
Fair Value
Money market funds
$
9,236

 
$

 
$

 
$
9,236

Corporate bonds
15,839

 

 
(18
)
 
15,821

Commercial paper
1,200

 

 

 
1,200

Government bonds
37,163

 

 
(57
)
 
37,106

Total cash equivalents and available-for-sale securities
$
63,438

 
$

 
$
(75
)
 
$
63,363

Classified as:
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
$
9,236

Available-for-sale securities - current
 
 
 
 
 
 
54,127

Available-for-sale securities - noncurrent
 
 
 
 
 
 

Total cash equivalents and available-for-sale securities
 
 
 
 
 
 
$
63,363


 
December 31, 2016
 
Amortized
Cost
 
Gross Unrealized
 
 
 
Gains
 
Losses
 
Fair Value
Money market funds
$
11,270

 
$

 
$

 
$
11,270

Corporate bonds
21,886

 

 
(45
)
 
21,841

Commercial paper
10,769

 

 

 
10,769

Government bonds
41,316

 
2

 
(29
)
 
41,289

Total cash equivalents and available-for-sale securities
$
85,241

 
$
2

 
$
(74
)
 
$
85,169

Classified as:
 
 
 
 
 
 
 
Cash equivalents
 
 
 
 
 
 
$
18,504

Available-for-sale securities - current
 
 
 
 
 
 
56,515

Available-for-sale securities - noncurrent
 
 
 
 
 
 
10,150

Total cash equivalents and available-for-sale securities
 
 
 
 
 
 
$
85,169



All available-for-sale securities - current held as of June 30, 2017 and December 31, 2016 had contractual maturities of less than one year. All available-for-sale securities - noncurrent held as of December 31, 2016 had contractual maturities of at least one year but less than two years. There were no available-for-sale securities - noncurrent held as of June 30, 2017. There have been no material realized gains or losses on available-for-sale securities for the periods presented.

Accrued Expenses and Other Payables

Accrued expenses and other payables consisted of the following (in thousands):
 
June 30, 2017
 
December 31, 2016
Accrued clinical and research related expenses
$
4,299

 
$
3,617

Accrued employee related expenses
1,338

 
1,420

Accrued professional service fees
669

 
115

Accrued milestone payment to former collaboration partner
250

 

Other
171

 
120

Total accrued expenses and other payables
$
6,727

 
$
5,272